Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted gene therapy

I R Hart1, R G Vile

  • 1Richard Dimbleby Department of Cancer Research, Rayne Institute, St Thomas' Hospital, London, UK.

British Medical Bulletin
|July 1, 1995
PubMed
Summary
This summary is machine-generated.

Targeted gene therapy using melanin biosynthesis gene promoters shows promise for cancer treatment. This approach, demonstrated in mouse models with immunostimulatory and prodrug genes, achieved significant anti-tumor effects, paving the way for human clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Gene therapy·2016
Same author

Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation.

Eye (London, England)·2013
Same author

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Oncogene·2013
Same author

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

Oral oncology·2012
Same author

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Gene therapy·2012
Same author

Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.

Gene therapy·2011
Same journal

Augmentation in Achilles tendon repair: evidence versus enthusiasm.

British medical bulletin·2026
Same journal

Regional musculoskeletal pain in workers-is the traditional medical model increasing disability?

British medical bulletin·2026
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
See all related articles

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research
  • Gene Therapy

Background:

  • Melanin biosynthesis is primarily confined to melanocytes due to transcriptional regulation of key enzymes.
  • Promoter sequences of these melanin synthesis genes can be leveraged for targeted gene expression.

Purpose of the Study:

  • To investigate the potential of using melanin biosynthesis gene promoters for transcriptional targeting of therapeutic genes.
  • To evaluate the anti-tumor efficacy of targeted gene therapy in preclinical models.

Main Methods:

  • Utilized 5'-flanking sequences of murine tyrosinase and tyrosinase-related protein 1 (TRP-1) genes.
  • Demonstrated transcriptional targeting in vitro and in vivo.
  • Employed interleukin-2 (IL-2) and Herpes Simplex Virus thymidine kinase (HSVtk) as model therapeutic genes in murine systems.

Related Experiment Videos

Main Results:

  • Transcriptional targeting of therapeutic genes was successfully achieved using melanin gene promoters.
  • Substantial anti-tumor effects were observed in murine models utilizing targeted gene therapy.
  • Demonstrated efficacy of both immunostimulatory (IL-2) and prodrug-activating (HSVtk) gene strategies.

Conclusions:

  • Transcriptional targeting via melanin biosynthesis gene promoters is a viable strategy for gene therapy.
  • Targeted gene therapy approaches show significant potential for anti-tumor effects.
  • The findings support the initiation of clinical evaluations in human patients.